RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
This partially randomized phase I trial is studying the side effects and the best dose of
RO4929097 when given together with exemestane and to see how well it works compared to
exemestane alone in treating premenopausal and postmenopausal patients with advanced or
metastatic breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone
therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body
makes. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth. Giving exemestane together with RO4929097 may kill more breast cancer cells.